NEWS

Drug Innovation Fault

Release time:

2017-09-01 13:39

As the number of drug approvals in the United States and Europe has steadily declined in recent years, a new page has been turned in drug production. Over the past few years, there has been a so-called "pharmaceutical innovation fault", that is, a large number of patent drugs have expired, and at the same time, a large number of new and promising drug candidates are lining up.

The FDA's "breakthrough treatment approval" process is very important in the rapid certification review process of new drugs, but it is also limited by a variety of other important factors, which have a direct or indirect impact on pharmaceutical manufacturing equipment.

When a large number of patents of more than 100 years of significance in the field of pharmaceutical production expire, it is also the end of the "blockbuster era. One of the reasons for the end of this era is that investors believe that the future of the pharmaceutical field is uncertain, and analysts have warned of a "drug innovation fault". It is believed that there is a crisis in the pharmaceutical industry on the basis of the annual registration of new drug approvals and the number of new drug research and development reserves. For more than ten years, pharmaceutical companies have invested a lot of money in drug research and development, but the number of new drugs approved for approval has remained stagnant, and even partially regressed-the work of the research and development department is more onerous than all other departments. This has led to a big explosion of costs.

In recent years, the number of new drugs that have been audited and certified has begun to increase, and there are new and better drugs on the market that can treat diseases that are difficult or impossible to treat, and the number of approved biological agents continues to grow.

Perhaps the FDA's "breakthrough treatment approval" process will be a turning point in determining the next decade. Although it is not yet very certain how long this breakthrough treatment process will be effective, new drugs with new and innovative treatments will be approved faster than before. This is naturally a good thing for millions of patients, but it is a huge challenge for all companies in the pharmaceutical industry. After a long period of drug development, efficacy verification and cost control, time to market has once again become the key word in the mouth of pharmaceutical companies. How to achieve the market in the shortest time, not only face the difficulties of the research and development process, the upgrading of production equipment, in order to be able to adapt to the future needs of drug production, but also the patent layout and the early stage of the market and many other factors.

　　https://news.pharmacodia.com/web/newinfo/information_8a2d98375df8dd3e015e137cd68c04fc.html